Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Nutt, JG
   Motor fluctuations and dyskinesia in Parkinson's disease
   PARKINSONISM & RELATED DISORDERS
   
   J.G. Nutt, "Motor fluctuations and dyskinesia in Parkinson's disease", PARKINS R D, 8(2), 2001, pp. 101-108
2. Joyce, JN; Ryoo, H; Gurevich, EV; Adler, C; Beach, T
   Ventral striatal D-3 receptors and Parkinson's disease
   PARKINSONISM & RELATED DISORDERS
   
   J.N. Joyce et al., "Ventral striatal D-3 receptors and Parkinson's disease", PARKINS R D, 7(3), 2001, pp. 225-230
3. Caraceni, T; Musicco, M
   Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study
   PARKINSONISM & RELATED DISORDERS
   
   T. Caraceni e M. Musicco, "Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study", PARKINS R D, 7(2), 2001, pp. 107-114
4. Depatie, L; Lal, S
   Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?
   JOURNAL OF PSYCHIATRY & NEUROSCIENCE
   
   L. Depatie e S. Lal, "Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?", J PSYCH NEU, 26(3), 2001, pp. 203-220
5. Rubenstein, LM; DeLeo, A; Chrischilles, EA
   Economic and health-related quality of life considerations of new therapies in Parkinson's disease
   PHARMACOECONOMICS
   
   L.M. Rubenstein et al., "Economic and health-related quality of life considerations of new therapies in Parkinson's disease", PHARMACOECO, 19(7), 2001, pp. 729-752
6. Erdal, KJ
   Depression and anxiety in persons with Parkinson's disease with and without "on-off" phenomena
   JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS
   
   K.J. Erdal, "Depression and anxiety in persons with Parkinson's disease with and without "on-off" phenomena", J CL P MED, 8(4), 2001, pp. 293-299
7. Furlanut, M; Furlanut, M; Benetello, P
   Monitoring of L-dopa concentrations in Parkinson's disease
   PHARMACOLOGICAL RESEARCH
   
   M. Furlanut et al., "Monitoring of L-dopa concentrations in Parkinson's disease", PHARMAC RES, 43(5), 2001, pp. 423-427
8. Lieberman, A; Minagar, A; Pinter, MM
   The efficacy of pramipexole in the treatment of Parkinson's disease
   REVIEWS IN CONTEMPORARY PHARMACOTHERAPY
   
   A. Lieberman et al., "The efficacy of pramipexole in the treatment of Parkinson's disease", REV CONT PH, 12(1-2), 2001, pp. 59-86
9. Marin, C; Jimenez, A; Bonastre, M; Vila, M; Agid, Y; Hirsch, EC; Tolosa, E
   LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in parkinsonian rats
   SYNAPSE
   
   C. Marin et al., "LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in parkinsonian rats", SYNAPSE, 42(1), 2001, pp. 40-47
10. Hardoff, R; Sula, M; Tamir, A; Soil, A; Front, A; Badarna, S; Honigman, S; Giladi, N
    Gastric emptying time and gastric motility in patients with Parkinson's disease
    MOVEMENT DISORDERS
    
    R. Hardoff et al., "Gastric emptying time and gastric motility in patients with Parkinson's disease", MOVEMENT D, 16(6), 2001, pp. 1041-1047
11. Koller, W; Lees, A; Doder, M; Hely, M
    Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations
    MOVEMENT DISORDERS
    
    W. Koller et al., "Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations", MOVEMENT D, 16(5), 2001, pp. 858-866
12. Ahlskog, JE; Muenter, MD
    Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
    MOVEMENT DISORDERS
    
    J.E. Ahlskog e M.D. Muenter, "Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature", MOVEMENT D, 16(3), 2001, pp. 448-458
13. Jankovic, J
    Parkinson's diseasetherapy: treatment of early and late disease
    CHINESE MEDICAL JOURNAL
    
    J. Jankovic, "Parkinson's diseasetherapy: treatment of early and late disease", CHIN MED J, 114(3), 2001, pp. 227-234
14. Djaldetti, R; Rosmarin, V; Ziv, I; Melamed, E
    The pharmacokinetic profile of the "first ever" oral dose of levodopa in de novo patients with Parkinson's disease
    CLINICAL NEUROPHARMACOLOGY
    
    R. Djaldetti et al., "The pharmacokinetic profile of the "first ever" oral dose of levodopa in de novo patients with Parkinson's disease", CLIN NEUROP, 24(2), 2001, pp. 95-98
15. Djaldetti, R; Melamed, E
    New therapies for Parkinson's disease
    JOURNAL OF NEUROLOGY
    
    R. Djaldetti e E. Melamed, "New therapies for Parkinson's disease", J NEUROL, 248(5), 2001, pp. 357-362
16. Wang, J; Liu, ZL; Chen, B
    Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson's disease
    NEUROSCIENCE LETTERS
    
    J. Wang et al., "Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson's disease", NEUROSCI L, 308(1), 2001, pp. 21-24
17. Fredriksson, A; Danysz, W; Quack, G; Archer, T
    Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice
    JOURNAL OF NEURAL TRANSMISSION
    
    A. Fredriksson et al., "Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice", J NEURAL TR, 108(2), 2001, pp. 167-187
18. Mungersdorf, M; Sommer, U; Sommer, M; Reichmann, H
    High-dose therapy with ropinirole in patients with Parkinson's disease
    JOURNAL OF NEURAL TRANSMISSION
    
    M. Mungersdorf et al., "High-dose therapy with ropinirole in patients with Parkinson's disease", J NEURAL TR, 108(11), 2001, pp. 1309-1317
19. Contin, M; Riva, R; Martinelli, P; Albani, F; Avoni, P; Baruzzi, A
    Levodopa therapy monitoring in patients with Parkinson disease: a kinetic-dynamic approach
    THERAPEUTIC DRUG MONITORING
    
    M. Contin et al., "Levodopa therapy monitoring in patients with Parkinson disease: a kinetic-dynamic approach", THER DRUG M, 23(6), 2001, pp. 621-629
20. Najib, J
    Entacapone: A catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease
    CLINICAL THERAPEUTICS
    
    J. Najib, "Entacapone: A catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease", CLIN THER, 23(6), 2001, pp. 802-832
21. Etminan, M; Samii, A; Takkouche, B; Rochon, PA
    Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease - A meta-analysis of randomised controlled trials
    DRUG SAFETY
    
    M. Etminan et al., "Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease - A meta-analysis of randomised controlled trials", DRUG SAFETY, 24(11), 2001, pp. 863-868
22. Agid, Y
    Levodopa - Is toxicity a myth?
    NEUROLOGY
    
    Y. Agid, "Levodopa - Is toxicity a myth?", NEUROLOGY, 57(10), 2001, pp. S46-S51
23. Rice, JE; Thompson, PD
    Movement disorders I: Parkinsonism and the akinetic-rigid syndromes
    MEDICAL JOURNAL OF AUSTRALIA
    
    J.E. Rice e P.D. Thompson, "Movement disorders I: Parkinsonism and the akinetic-rigid syndromes", MED J AUST, 174(7), 2001, pp. 357-363
24. Manson, AJ; Hanagasi, H; Turner, K; Patsalos, PN; Carey, P; Ratnaraj, N; Lees, AJ
    Intravenous apomorphine therapy in Parkinson's disease - Clinical and pharmacokinetic observations
    BRAIN
    
    A.J. Manson et al., "Intravenous apomorphine therapy in Parkinson's disease - Clinical and pharmacokinetic observations", BRAIN, 124, 2001, pp. 331-340
25. Dewey, RB; Hutton, JT; LeWitt, PA; Factor, SA
    A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for Parkinsonian off-state events
    ARCHIVES OF NEUROLOGY
    
    R.B. Dewey et al., "A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for Parkinsonian off-state events", ARCH NEUROL, 58(9), 2001, pp. 1385-1392
26. Shoulson, I; Lang, A; Fahn, S; McDermott, M; Kieburtz, K; Schwid, S; Kayson, E; Chase, T; Greenamyre, T; Penney, J; Frucht, S; Winfield, H; Goetz, C; Blasucci, L; Nutt, J; Carter, J; Morehouse, S; Rajput, A; Ewanishin, M; Johnston, L; Casaceli, C; Day, D; Hodgeman, K; Laroia, N; de Marcaida, JA; Orme, C; Watts, A; Natarajan, R; Huang, P; Tariot, P; Cox, C; Leventhal, C
    Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trialof remacemide in advanced Parkinson disease
    ARCHIVES OF NEUROLOGY
    
    I. Shoulson et al., "Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trialof remacemide in advanced Parkinson disease", ARCH NEUROL, 58(10), 2001, pp. 1660-1668
27. Nilsson, D; Nyholm, D; Aquilonius, SM
    Duodenal levodopa infusion in Parkinson's disease - long-term experience
    ACTA NEUROLOGICA SCANDINAVICA
    
    D. Nilsson et al., "Duodenal levodopa infusion in Parkinson's disease - long-term experience", ACT NEUR SC, 104(6), 2001, pp. 343-348
28. Brooks, DJ; Forsyth, D; Playfer, JR; Williams, AC
    The role of entacapone in the management of Parkinson's disease
    HOSPITAL MEDICINE
    
    D.J. Brooks et al., "The role of entacapone in the management of Parkinson's disease", HOSP MED, 61(4), 2000, pp. 267-271
29. Stern, MB
    The early treatment of Parkinson's disease: levodopa, dopamine agonists orboth
    PARKINSONISM & RELATED DISORDERS
    
    M.B. Stern, "The early treatment of Parkinson's disease: levodopa, dopamine agonists orboth", PARKINS R D, 7(1), 2000, pp. 27-33
30. Rinne, UK
    Treatment of early Parkinson's disease
    PARKINSONISM & RELATED DISORDERS
    
    U.K. Rinne, "Treatment of early Parkinson's disease", PARKINS R D, 7(1), 2000, pp. 59-62
31. Kondo, T
    Treatment of Parkinson's disease in Japan
    PARKINSONISM & RELATED DISORDERS
    
    T. Kondo, "Treatment of Parkinson's disease in Japan", PARKINS R D, 7(1), 2000, pp. 71-77
32. Olanow, CW; Stocchi, F
    Why delaying levodopa is a good treatment strategy in early Parkinson's disease
    EUROPEAN JOURNAL OF NEUROLOGY
    
    C.W. Olanow e F. Stocchi, "Why delaying levodopa is a good treatment strategy in early Parkinson's disease", EUR J NEUR, 7, 2000, pp. 3-8
33. Contin, M; Riva, R; Albani, F; Baruzzi, A
    Pharmacokinetic optimisation of dopamine receptor agonist therapy for Parkinson's disease
    CNS DRUGS
    
    M. Contin et al., "Pharmacokinetic optimisation of dopamine receptor agonist therapy for Parkinson's disease", CNS DRUGS, 14(6), 2000, pp. 439-455
34. Bonnet, AM
    Involvement of non-dopaminergic pathways in Parkinson's disease - Pathophysiology and therapeutic implications
    CNS DRUGS
    
    A.M. Bonnet, "Involvement of non-dopaminergic pathways in Parkinson's disease - Pathophysiology and therapeutic implications", CNS DRUGS, 13(5), 2000, pp. 351-364
35. Kulisevsky, J
    Role of dopamine in learning and memory - Implications for the treatment of cognitive dysfunction in patients with Parkinson's disease
    DRUGS & AGING
    
    J. Kulisevsky, "Role of dopamine in learning and memory - Implications for the treatment of cognitive dysfunction in patients with Parkinson's disease", DRUG AGING, 16(5), 2000, pp. 365-379
36. Young, LR; Justice, LN
    Parkinson's disease: Focus on management alternatives
    AMERICAN JOURNAL OF MANAGED CARE
    
    L.R. Young e L.N. Justice, "Parkinson's disease: Focus on management alternatives", AM J M CARE, 6(1), 2000, pp. 93-113
37. Hely, MA; Fung, VSC; Morris, JGL
    Treatment of Parkinson's disease
    JOURNAL OF CLINICAL NEUROSCIENCE
    
    M.A. Hely et al., "Treatment of Parkinson's disease", J CL NEUROS, 7(6), 2000, pp. 484-494
38. Henderson, MJ; Mellers, JDC
    Psychosis in Parkinson's disease: 'between a rock and a hard place'
    INTERNATIONAL REVIEW OF PSYCHIATRY
    
    M.J. Henderson e J.D.C. Mellers, "Psychosis in Parkinson's disease: 'between a rock and a hard place'", INT R PSYC, 12(4), 2000, pp. 319-334
39. Marin, C; Jimenez, A; Bonastre, M; Chase, TN; Tolosa, E
    Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in parkinsonian rats
    SYNAPSE
    
    C. Marin et al., "Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in parkinsonian rats", SYNAPSE, 36(4), 2000, pp. 267-274
40. Poewe, W; Wenning, GK
    Apomorphine: An underutilized therapy for Parkinson's disease
    MOVEMENT DISORDERS
    
    W. Poewe e G.K. Wenning, "Apomorphine: An underutilized therapy for Parkinson's disease", MOVEMENT D, 15(5), 2000, pp. 789-794
41. Luginger, E; Wenning, GK; Bosch, S; Poewe, W
    Beneficial effects of amantadine on L-Dopa-induced dyskinesias in Parkinson's disease
    MOVEMENT DISORDERS
    
    E. Luginger et al., "Beneficial effects of amantadine on L-Dopa-induced dyskinesias in Parkinson's disease", MOVEMENT D, 15(5), 2000, pp. 873-878
42. Goetz, CG; Stebbins, GT; Blasucci, LM
    Differential progression of motor impairment in levodopa-treated Parkinson's disease
    MOVEMENT DISORDERS
    
    C.G. Goetz et al., "Differential progression of motor impairment in levodopa-treated Parkinson's disease", MOVEMENT D, 15(3), 2000, pp. 479-484
43. Factor, SA; Molho, ES
    Emergency department presentations of patients with Parkinson's disease
    AMERICAN JOURNAL OF EMERGENCY MEDICINE
    
    S.A. Factor e E.S. Molho, "Emergency department presentations of patients with Parkinson's disease", AM J EMER M, 18(2), 2000, pp. 209-215
44. Metman, LV; Del Dotto, P; LePoole, K; Konitsiotis, S; Fang, J; Chase, TN
    Amantadine for levodopa-induced dyskinesias
    NERVENHEILKUNDE
    
    L.V. Metman et al., "Amantadine for levodopa-induced dyskinesias", NERVENHEILK, 19(5), 2000, pp. 276-279
45. Ogawa, N
    Factors affecting levodopa effects in Parkinson's disease
    ACTA MEDICA OKAYAMA
    
    N. Ogawa, "Factors affecting levodopa effects in Parkinson's disease", ACT MED OKA, 54(3), 2000, pp. 95-101
46. Bejjani, BP; Arnulf, I; Demeret, S; Damier, P; Bonnet, AM; Houeto, JL; Agid, Y
    Levodopa-induced dyskinesias in Parkinson's disease: Is sensitization reversible?
    ANNALS OF NEUROLOGY
    
    B.P. Bejjani et al., "Levodopa-induced dyskinesias in Parkinson's disease: Is sensitization reversible?", ANN NEUROL, 47(5), 2000, pp. 655-658
47. Calabresi, P; Giacomini, P; Centonze, D; Bernardi, G
    Levodopa-induced dyskinesia: A pathological form of striatal synaptic plasticity?
    ANNALS OF NEUROLOGY
    
    P. Calabresi et al., "Levodopa-induced dyskinesia: A pathological form of striatal synaptic plasticity?", ANN NEUROL, 47(4), 2000, pp. S60-S69
48. Nutt, JG
    Clinical pharmacology of levodopa-induced dyskinesia
    ANNALS OF NEUROLOGY
    
    J.G. Nutt, "Clinical pharmacology of levodopa-induced dyskinesia", ANN NEUROL, 47(4), 2000, pp. S160-S166
49. Rabey, JM; Sagi, I; Huberman, M; Melamed, E; Korczyn, A; Giladi, N; Inzelberg, R; Djaldetti, R; Klein, C; Berecz, G
    Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa
    CLINICAL NEUROPHARMACOLOGY
    
    J.M. Rabey et al., "Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa", CLIN NEUROP, 23(6), 2000, pp. 324-330
50. Tahar, AH; Gregoire, L; Bangassoro, E; Bedard, PJ
    Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys
    CLINICAL NEUROPHARMACOLOGY
    
    A.H. Tahar et al., "Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys", CLIN NEUROP, 23(4), 2000, pp. 195-202
51. Hauser, RA; Friedlander, J; Zesiewicz, TA; Adler, CH; Seeberger, LC; O'Brien, CF; Molho, ES; Factor, SA
    A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia
    CLINICAL NEUROPHARMACOLOGY
    
    R.A. Hauser et al., "A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia", CLIN NEUROP, 23(2), 2000, pp. 75-81
52. Reichmann, H; Lachenmayer, L
    The non-ergot-agonist ropinirole in the treatment of Parkinson's disease
    AKTUELLE NEUROLOGIE
    
    H. Reichmann e L. Lachenmayer, "The non-ergot-agonist ropinirole in the treatment of Parkinson's disease", AKT NEUROL, 27(7), 2000, pp. 318-324
53. de la Fuente-Fernandez, R; Pal, PK; Vingerhoets, FJG; Kishore, A; Schulzer, M; Mak, EK; Ruth, TJ; Snow, BJ; Calne, DB; Stoessl, AJ
    Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations
    JOURNAL OF NEURAL TRANSMISSION
    
    R. de la Fuente-Fernandez et al., "Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations", J NEURAL TR, 107(1), 2000, pp. 49-57
54. Woitalla, D; Karwasz, R; Muller, T; Przuntek, H; Kuhn, W
    The activity of Catechol-O-Methyltransferase in parkinsonian patients with"on-off fluctuations"
    JOURNAL OF NEURAL TRANSMISSION
    
    D. Woitalla et al., "The activity of Catechol-O-Methyltransferase in parkinsonian patients with"on-off fluctuations"", J NEURAL TR, 107(1), 2000, pp. 105-111
55. Berchou, RC
    Maximizing the benefit of pharmacotherapy in Parkinson's disease
    PHARMACOTHERAPY
    
    R.C. Berchou, "Maximizing the benefit of pharmacotherapy in Parkinson's disease", PHARMACOTHE, 20(1), 2000, pp. 33S-41S
56. Kashihara, K; Manabe, Y; Shiro, Y; Warita, H; Abe, K
    Effects of repeated methyl levodopa administration on apomorphine sensitivity of rotational behavior and striatal Fos expression of rats with unilateral 6-OHDA lesions
    NEUROSCIENCE RESEARCH
    
    K. Kashihara et al., "Effects of repeated methyl levodopa administration on apomorphine sensitivity of rotational behavior and striatal Fos expression of rats with unilateral 6-OHDA lesions", NEUROSCI RE, 38(3), 2000, pp. 273-279
57. Nutt, JG; Obeso, JA; Stocchi, F
    Continuous dopamine-receptor stimulation in advanced Parkinson's disease
    TRENDS IN NEUROSCIENCES
    
    J.G. Nutt et al., "Continuous dopamine-receptor stimulation in advanced Parkinson's disease", TRENDS NEUR, 23(10), 2000, pp. S109-S115
58. Broussolle, E
    Dopa-therapy in the treatment of early stage Parkinson's disease
    REVUE NEUROLOGIQUE
    
    E. Broussolle, "Dopa-therapy in the treatment of early stage Parkinson's disease", REV NEUROL, 156, 2000, pp. 91-97
59. Brefel-Courbon, C
    What drug strategies are advisable for patients with advanced-stage Parkinsons's (working session)
    REVUE NEUROLOGIQUE
    
    C. Brefel-Courbon, "What drug strategies are advisable for patients with advanced-stage Parkinsons's (working session)", REV NEUROL, 156, 2000, pp. 120-159
60. Thobois, S
    Surgical treatments in Parkinson's disease
    REVUE NEUROLOGIQUE
    
    S. Thobois, "Surgical treatments in Parkinson's disease", REV NEUROL, 156, 2000, pp. 218-250
61. Blond, S; Touzet, G; Krystkowiak, P; Defebvre, L; Destee, A
    Neurosurgical treatment of Parkinson's disease: which technique is best?
    REVUE NEUROLOGIQUE
    
    S. Blond et al., "Neurosurgical treatment of Parkinson's disease: which technique is best?", REV NEUROL, 156, 2000, pp. 257-269
62. Munchau, A; Bhatia, KP
    Pharmacological treatment of Parkinson's disease
    POSTGRADUATE MEDICAL JOURNAL
    
    A. Munchau e K.P. Bhatia, "Pharmacological treatment of Parkinson's disease", POSTG MED J, 76(900), 2000, pp. 602-610
63. Nieuwboer, A; De Weerdt, W; Dom, R; Bogaerts, K; Nuyens, G
    Development of an activity scale for individuals with advanced Parkinson disease: Reliability and "on-off" variability
    PHYSICAL THERAPY
    
    A. Nieuwboer et al., "Development of an activity scale for individuals with advanced Parkinson disease: Reliability and "on-off" variability", PHYS THER, 80(11), 2000, pp. 1087-1096
64. Kumar, R; Lang, AE; Rodriguez-Oroz, MC; Lozano, AM; Limousin, P; Pollak, P; Benabid, AL; Guridi, J; Ramos, E; van der Linden, C; Vandewalle, A; Caemaert, J; Lannoo, E; van den Abbeele, D; Vingerhoets, G; Wolters, M; Obeso, JA
    Deep brain simulation of the globus pallidus pars interna in advanced Parkinson's disease
    NEUROLOGY
    
    R. Kumar et al., "Deep brain simulation of the globus pallidus pars interna in advanced Parkinson's disease", NEUROLOGY, 55(12), 2000, pp. S34-S39
65. Rodriguez-Oroz, MC; Gorospe, A; Guridi, J; Ramos, E; Linazasoro, G; Rodriguez-Palmero, M; Obeso, JA
    Bilateral deep brain stimulation of the subthalamic nucleus in Parkinson'sdisease
    NEUROLOGY
    
    M.C. Rodriguez-Oroz et al., "Bilateral deep brain stimulation of the subthalamic nucleus in Parkinson'sdisease", NEUROLOGY, 55(12), 2000, pp. S45-S51
66. Koller, WC
    Levodopa in the treatment of Parkinson's disease
    NEUROLOGY
    
    W.C. Koller, "Levodopa in the treatment of Parkinson's disease", NEUROLOGY, 55, 2000, pp. S2-S7
67. Tsang, KL; Ho, SL; Lo, SK
    Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations
    NEUROLOGY
    
    K.L. Tsang et al., "Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations", NEUROLOGY, 54(12), 2000, pp. 2292-2298
68. Cersosimo, MG; Scorticati, MC; Micheli, FE
    Amantadine for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
    MEDICINA-BUENOS AIRES
    
    M.G. Cersosimo et al., "Amantadine for the treatment of levodopa-induced dyskinesias in Parkinson's disease.", MEDICINA, 60(3), 2000, pp. 321-325
69. Charlton, CG; Crowell, B
    Effects of dopamine metabolites on locomotor activities and on the bindingof dopamine: Relevance to the side effects of L-dopa
    LIFE SCIENCES
    
    C.G. Charlton e B. Crowell, "Effects of dopamine metabolites on locomotor activities and on the bindingof dopamine: Relevance to the side effects of L-dopa", LIFE SCI, 66(22), 2000, pp. 2159-2171
70. Piccini, P; Brooks, DJ; Korpela, K; Pavese, N; Karlsson, M; Gordin, A
    The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
    
    P. Piccini et al., "The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease", J NE NE PSY, 68(5), 2000, pp. 589-594
71. Ravenscroft, P; Brotchie, J
    NMDA receptors in the basal ganglia
    JOURNAL OF ANATOMY
    
    P. Ravenscroft e J. Brotchie, "NMDA receptors in the basal ganglia", J ANAT, 196, 2000, pp. 577-585
72. Schrag, A; Quinn, N
    Dyskinesias and motor fluctuations in Parkinson's disease - A community-based study
    BRAIN
    
    A. Schrag e N. Quinn, "Dyskinesias and motor fluctuations in Parkinson's disease - A community-based study", BRAIN, 123, 2000, pp. 2297-2305
73. Reardon, KA; Mendelsohn, FAO; Chai, SY; Horne, MK
    The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE
    
    K.A. Reardon et al., "The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease", AUST NZ J M, 30(1), 2000, pp. 48-53
74. Dodel, RC; Eggert, K; Oertel, WH
    Economical research on Parkinson's disease: a review of the literature
    EUROPEAN JOURNAL OF NEUROLOGY
    
    R.C. Dodel et al., "Economical research on Parkinson's disease: a review of the literature", EUR J NEUR, 6, 1999, pp. S3-S15
75. Wiseman, LR; Fitton, A
    Cabergoline - A review of its efficacy in the treatment of Parkinson's disease
    CNS DRUGS
    
    L.R. Wiseman e A. Fitton, "Cabergoline - A review of its efficacy in the treatment of Parkinson's disease", CNS DRUGS, 12(6), 1999, pp. 485-497
76. Durif, F
    Treating and preventing levodopa-induced dyskinesias - Current and future strategies
    DRUGS & AGING
    
    F. Durif, "Treating and preventing levodopa-induced dyskinesias - Current and future strategies", DRUG AGING, 14(5), 1999, pp. 337-345
77. Liu, H; Iacono, RP; Schoonenberg, T; Kuniyoshi, S; Buchholz, J
    A comparative study on neurochemistry of cerebrospinal fluid in advanced Parkinson's disease
    NEUROBIOLOGY OF DISEASE
    
    H. Liu et al., "A comparative study on neurochemistry of cerebrospinal fluid in advanced Parkinson's disease", NEUROBIOL D, 6(1), 1999, pp. 35-42
78. Weiner, WJ
    The initial treatment of Parkinson's disease should begin with levodopa
    MOVEMENT DISORDERS
    
    W.J. Weiner, "The initial treatment of Parkinson's disease should begin with levodopa", MOVEMENT D, 14(5), 1999, pp. 716-724
79. Hagell, P; Widner, H
    Clinical rating of dyskinesias in Parkinson's disease: Use and reliabilityof a new rating scale
    MOVEMENT DISORDERS
    
    P. Hagell e H. Widner, "Clinical rating of dyskinesias in Parkinson's disease: Use and reliabilityof a new rating scale", MOVEMENT D, 14(3), 1999, pp. 448-455
80. Agid, Y; Destee, A; Durif, F; Montastruc, JL; Pedarriosse, AM; Deptula, D; Hoffman-La Roche, F; Pollak, P; Bonnet, AM; Allain, H; le Cavorzin, P; Barroche, G; Blin, O; Cesaro, P; Chazot, G; Broussolle, E; Leduc, V; Debilly, B; Feve, JR; Geraud, G; Fabre, N; Gu, C; Gil, R; Henry, P; Tison, F; Ansquer, O; Brefel, C; Payen, I; Said, G; Plante, V; Touchon, J; Cesari, JB; Camu, W; Bennys, K; Viallet, F; Warter, JM; Tranchant, C; Ziegler, M
    Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients
    MOVEMENT DISORDERS
    
    Y. Agid et al., "Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients", MOVEMENT D, 14(1), 1999, pp. 38-44
81. Goetz, CG
    Rating scales for dyskinesias in Parkinson's disease
    MOVEMENT DISORDERS
    
    C.G. Goetz, "Rating scales for dyskinesias in Parkinson's disease", MOVEMENT D, 14, 1999, pp. 48-53
82. Widner, H; Defer, GL
    Dyskinesias assessment: From CAPIT to CAPSIT
    MOVEMENT DISORDERS
    
    H. Widner e G.L. Defer, "Dyskinesias assessment: From CAPIT to CAPSIT", MOVEMENT D, 14, 1999, pp. 60-66
83. Ceballos-Baumann, AO
    New aspects in the treatment of Parkinson's disease
    NERVENHEILKUNDE
    
    A.O. Ceballos-Baumann, "New aspects in the treatment of Parkinson's disease", NERVENHEILK, 18(9), 1999, pp. 452-459
84. Contin, M; Riva, R; Martinelli, P; Cortelli, P; Albani, F; Baruzzi, A
    Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor responsefluctuations in Parkinson's disease
    CLINICAL NEUROPHARMACOLOGY
    
    M. Contin et al., "Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor responsefluctuations in Parkinson's disease", CLIN NEUROP, 22(6), 1999, pp. 351-355
85. Merello, M; Nouzeilles, MI; Cammarota, A; Leiguarda, R
    Effect of memantine (NMDA antagonist) on Parkinson's disease: A double-blind crossover randomized study
    CLINICAL NEUROPHARMACOLOGY
    
    M. Merello et al., "Effect of memantine (NMDA antagonist) on Parkinson's disease: A double-blind crossover randomized study", CLIN NEUROP, 22(5), 1999, pp. 273-276
86. Barboi, AC; Goetz, CG
    Clinical Neuropharmacology - Patient management series Parkinson's disease
    CLINICAL NEUROPHARMACOLOGY
    
    A.C. Barboi e C.G. Goetz, "Clinical Neuropharmacology - Patient management series Parkinson's disease", CLIN NEUROP, 22(4), 1999, pp. 184-191
87. de la Fuente-Fernandez, R
    Drug-induced motor complications in dopa-responsive dystonia: Implicationsfor the pathogenesis of dyskinesias and motor fluctuations
    CLINICAL NEUROPHARMACOLOGY
    
    R. de la Fuente-Fernandez, "Drug-induced motor complications in dopa-responsive dystonia: Implicationsfor the pathogenesis of dyskinesias and motor fluctuations", CLIN NEUROP, 22(4), 1999, pp. 216-219
88. Ondo, W; Hunter, C; Almaguer, M; Gancher, S; Jankovic, J
    Efficacy and tolerability of a novel sublingual apomorphine preparation inpatients with fluctuating Parkinson's disease
    CLINICAL NEUROPHARMACOLOGY
    
    W. Ondo et al., "Efficacy and tolerability of a novel sublingual apomorphine preparation inpatients with fluctuating Parkinson's disease", CLIN NEUROP, 22(1), 1999, pp. 1-4
89. Napolitano, A; Del Dotto, P; Petrozzi, L; Dell'Agnello, G; Bellini, G; Gambaccini, G; Bonuccelli, U
    Pharmacokinetics and pharmacodynamics of L-DOPA after acute and 6-week tolcapone administration in patients with Parkinson's disease
    CLINICAL NEUROPHARMACOLOGY
    
    A. Napolitano et al., "Pharmacokinetics and pharmacodynamics of L-DOPA after acute and 6-week tolcapone administration in patients with Parkinson's disease", CLIN NEUROP, 22(1), 1999, pp. 24-29
90. Manyam, BV; Hare, TA; Robbs, R; Cubberley, VB
    Evaluation of equivalent efficacy of Sinemet and Sinemet CR in patients with Parkinson's disease applying levodopa dosage conversion formula
    CLINICAL NEUROPHARMACOLOGY
    
    B.V. Manyam et al., "Evaluation of equivalent efficacy of Sinemet and Sinemet CR in patients with Parkinson's disease applying levodopa dosage conversion formula", CLIN NEUROP, 22(1), 1999, pp. 33-39
91. Mendis, T; Suchowersky, O; Lang, A; Gauthier, S
    Management of Parkinson's disease - A review of current and new therapies
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
    
    T. Mendis et al., "Management of Parkinson's disease - A review of current and new therapies", CAN J NEUR, 26(2), 1999, pp. 89-103
92. King, DB
    Parkinson's disease - Levodopa complications
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
    
    D.B. King, "Parkinson's disease - Levodopa complications", CAN J NEUR, 26, 1999, pp. S13-S20
93. Neef, C; van Laar, T
    Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease
    CLINICAL PHARMACOKINETICS
    
    C. Neef e T. van Laar, "Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease", CLIN PHARMA, 37(3), 1999, pp. 257-271
94. Fredriksson, A; Palomo, T; Chase, T; Archer, T
    Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: effects of glutamate antagonists
    JOURNAL OF NEURAL TRANSMISSION
    
    A. Fredriksson et al., "Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: effects of glutamate antagonists", J NEURAL TR, 106(3-4), 1999, pp. 283-300
95. Gottwald, MD
    Maximizing the benefit : risk ratio of levodopa therapy in Parkinson's disease
    PHARMACOTHERAPY
    
    M.D. Gottwald, "Maximizing the benefit : risk ratio of levodopa therapy in Parkinson's disease", PHARMACOTHE, 19(11), 1999, pp. 162S-168S
96. Lee, WY; Chang, JW; Nemeth, NL; Kang, UJ
    Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3,4-dihydroxyphenylalanine administrationin Parkinsonian rats
    JOURNAL OF NEUROSCIENCE
    
    W.Y. Lee et al., "Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3,4-dihydroxyphenylalanine administrationin Parkinsonian rats", J NEUROSC, 19(8), 1999, pp. 3266-3274
97. Bonifati, V; Meco, G
    New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease
    PHARMACOLOGY & THERAPEUTICS
    
    V. Bonifati e G. Meco, "New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease", PHARM THERA, 81(1), 1999, pp. 1-36
98. Broussolle, E
    Arguments favoring early treatment of Parkinson's disease with L-Dopa
    REVUE NEUROLOGIQUE
    
    E. Broussolle, "Arguments favoring early treatment of Parkinson's disease with L-Dopa", REV NEUROL, 155(1), 1999, pp. 27-33
99. Koller, WC; Hutton, JT; Tolosa, E; Capilldeo, R
    Immediate-release and controlled-release carbidopa/levodopa in PD - A 5-year randomized multicenter study
    NEUROLOGY
    
    W.C. Koller et al., "Immediate-release and controlled-release carbidopa/levodopa in PD - A 5-year randomized multicenter study", NEUROLOGY, 53(5), 1999, pp. 1012-1019
100. Zappia, M; Oliveri, RL; Montesanti, R; Rizzo, M; Bosco, D; Plastino, M; Crescibene, L; Bastone, L; Aguglia, U; Gambardella, A; Quattrone, A
     Loss of long-duration response to levodopa over time in PD - Implications for wearing-off
     NEUROLOGY
     
     M. Zappia et al., "Loss of long-duration response to levodopa over time in PD - Implications for wearing-off", NEUROLOGY, 52(4), 1999, pp. 763-767